Human KIM-1 amino acid sequence (SEQ ID NO:1):

1 SVKVGGEAGPSVTLPCHYSGAVTSMCWNRGSCSLFTCQNGIVWTNGTHVTYRKDTRYKLL
61 GDLSRRDVSLTIENTAVSDSGVYCCRVEHRGWFNDMKITVSLEIVPPKVTTTPIVTTVPT
121 VTTVRTSTTVPTTTTVPTTTVPTTMSIPTTTTVPTTMTVSTTTSVPTTTSIPTTTSVPVT
181 TTVSTFVPPMPLPRQNHEPVATSPSSPQPAETHPTTLQGAIRREPTSSPLYSYTTDGNDT
241 **VTESSDGLWNNNQTQLFLEHSLLTANTTK**GIYAGVCISVLVLLALLGVIIAKKYFFKKEV
301 QQLSVSFSSLQIKALQNAVEKEVQAEDNIYIENSLYATD

ITALIC = IgV domain
UNDERLINE = mucin domain
BOLD = stalk domain
DOUBLE UNDERLINE = transmembrane domain
LIGHT SHADED = sequences containing the sialic acid binding motif
DARK SHADED AND UNDERLINED = sequence corresponding to mouse alternatively spliced variant

Fig. 1



% EOSINOPHILS
60
50
40
30
20
10
0
NEGATIVE CONTROL
UNTREATED CONTROL
3A2
ISOTYPE CONTROL

Fig. 2



TRITIATED THYMIDINE (cpm)
250000
200000
150000
100000
50000
0
NEGATIVE CONTROL
UNTREATED CONTROL
3A2
ISOTYPE CONTROL

Fig. 3



20000
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
PICAGRAMS/ml
CONTROL
OVA
3A2
IL-4
IL-5
IL-10

Fig. 4




Fig. 5



EOSINOPHILS
% CELLS REPRESENTED IN BAL
50
40
30
20
10
0
PBS
OVA
4A2
LYMPHOCYTES
% CELLS REPRESENTED IN BAL
4
3
2
1
0
PBS
OVA
4A2

Fig. 6



CYTOKINE EXPRESSION BY DRAINING LYMPH NODE CELLS
IL-4
IL-5
IL-10
IL-13
PBS
OVA
4A2
pg/ml

Fig. 7




BAL CELLULARITY AFTER
THERAPEUTIC TREATMENT WITH mAb 4A2
% EOSINOPHILS
14
12
10
8
6
4
2
0
OVA
4A2
ISOTYPE
CONTROL mAb

Fig. 8



y = ((A - D)/(1 + (x/C)^B)) + D:	A	B	C	D	R^2
○ muKIM1 (muKIM1: CONCENTRATION vs MEAN VALUE)	0.027	1.414	18.352	2.237	0.999
□ muKIM1 DBA (muKIM1 DBA: CONCENTRATION vs MEAN VAL...	0.047	1.448	20.303	2.278	1
△ RAT KIM1 (RAT KIM1: CONCENTRATION vs MEAN VALUE)	-0.007	1.278	6.09	0.047	0.885
◇ HUMAN KIM1 (HUMAN KIM1: CONCENTRATION vs MEAN VALUE)	-0.026	22.339	491.314	-0.01	0.685

Fig. 9

SEQUENCE LISTING

<110> Biogen Idec MA Inc
Rennert, Paul
McCoon, Patricia
Bailly, Veronique
Lugovskoy, Alexey

<120> KIM-1 ANTIBODIES FOR TREATMENT OF Th2-MEDIATED CONDITIONS

<130> P0643

<150> 60/657,789
<151> 2005-03-02

<160> 2

<170> PatentIn version 3.3

<210> 1
<211> 339
<212> PRT
<213> human

<400> 1

Ser Val Lys Val Gly Gly Glu Ala Gly Pro Ser Val Thr Leu Pro Cys
1 5 10 15

His Tyr Ser Gly Ala Val Thr Ser Met Cys Trp Asn Arg Gly Ser Cys
20 25 30

Ser Leu Phe Thr Cys Gln Asn Gly Ile Val Trp Thr Asn Gly Thr His
35 40 45

Val Thr Tyr Arg Lys Asp Thr Arg Tyr Lys Leu Leu Gly Asp Leu Ser
50 55 60

Arg Arg Asp Val Ser Leu Thr Ile Glu Asn Thr Ala Val Ser Asp Ser
65 70 75 80

Gly Val Tyr Cys Cys Arg Val Glu His Arg Gly Trp Phe Asn Asp Met
85 90 95

Lys Ile Thr Val Ser Leu Glu Ile Val Pro Pro Lys Val Thr Thr Thr
100 105 110

Pro Ile Val Thr Thr Val Pro Thr Val Thr Thr Val Arg Thr Ser Thr
115 120 125

Thr Val Pro Thr Thr Thr Thr Val Pro Thr Thr Thr Val Pro Thr Thr
130 135 140

Met Ser Ile Pro Thr Thr Thr Thr Val Pro Thr Thr Met Thr Val Ser
145 150 155 160

Thr Thr Thr Ser Val Pro Thr Thr Thr Ser Ile Pro Thr Thr Thr Ser
165 170 175

Val Pro Val Thr Thr Thr Val Ser Thr Phe Val Pro Pro Met Pro Leu
180 185 190

Pro Arg Gln Asn His Glu Pro Val Ala Thr Ser Pro Ser Ser Pro Gln
195 200 205

Pro Ala Glu Thr His Pro Thr Thr Leu Gln Gly Ala Ile Arg Arg Glu
210 215 220

Pro Thr Ser Ser Pro Leu Tyr Ser Tyr Thr Thr Asp Gly Asn Asp Thr
225 230 235 240

Val Thr Glu Ser Ser Asp Gly Leu Trp Asn Asn Asn Gln Thr Gln Leu
245 250 255

Phe Leu Glu His Ser Leu Leu Thr Ala Asn Thr Thr Lys Gly Ile Tyr
260 265 270

Ala Gly Val Cys Ile Ser Val Leu Val Leu Leu Ala Leu Leu Gly Val
275 280 285

Ile Ile Ala Lys Lys Tyr Phe Phe Lys Lys Glu Val Gln Gln Leu Ser
290 295 300

Val Ser Phe Ser Ser Leu Gln Ile Lys Ala Leu Gln Asn Ala Val Glu
305 310 315 320

Lys Glu Val Gln Ala Glu Asp Asn Ile Tyr Ile Glu Asn Ser Leu Tyr
325 330 335

Ala Thr Asp

<210> 2
<211> 23
<212> PRT
<213> Mus musculus

<400> 2

Glu Pro Thr Thr Phe Cys Pro His Glu Thr Thr Ala Glu Val Thr Gly
1 5 10 15

Ile Pro Ser His Thr Pro Thr
20